TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman

aTyr Pharma reported a wider-than-expected quarterly loss and faces securities litigation over alleged misleading statements about its drug Efzofitimod's efficacy, with stock price dropping 83% after disappointing clinical trial results.

Insights
ATYR   negative

Company reported financial losses, missed analyst estimates, experienced significant stock price decline, and is facing a class action lawsuit alleging misleading investor communications about drug trial results